GLP-1 medications and cancer have become a major topic of discussion following new research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. While medications such as semaglutide and tirzepatide are best known for helping patients lose weight and improve metabolic health, researchers are now investigating whether they may also help reduce cancer progression in certain obesity-related cancers. The findings are generating excitement among scientists and healthcare providers, but understanding what the research actually shows—and what it does not show—is important for patients considering GLP-1 therapy.
What Did the New Study Find?
Researchers from the Cleveland Clinic analyzed health records from more than 12,000 patients diagnosed with stage I, II, or III obesity-related cancers. They compared patients taking GLP-1 medications with similar patients taking older diabetes medications known as DPP-4 inhibitors.
The results were noteworthy.
Patients using GLP-1 medications experienced significantly lower rates of progression to stage IV (metastatic) cancer in several cancer types:
- Non-small cell lung cancer: approximately 50% lower risk of progression
- Breast cancer: approximately 43% lower risk of progression
- Liver cancer: approximately 38% lower risk of progression
- Colorectal cancer: approximately 31% lower risk of progression
Researchers also observed a trend toward reduced progression in prostate, pancreatic, and kidney cancers, although those findings were not statistically significant.
Why Might GLP-1 Medications Affect Cancer?
Scientists do not yet know the exact mechanism, but several theories exist.
1. Reduced Chronic Inflammation
Obesity is associated with chronic low-grade inflammation throughout the body. Persistent inflammation can contribute to cancer growth and progression.
GLP-1 medications have been shown to reduce inflammatory markers, potentially creating a less favorable environment for cancer cells.
2. Improved Metabolic Health
High insulin levels and insulin resistance have been linked to several obesity-related cancers. GLP-1 medications improve insulin sensitivity and reduce circulating insulin levels.
Because some tumors may use insulin-related pathways to support growth, improved metabolic health could play a protective role.
3. Significant Weight Loss
Excess body fat is associated with increased risk for at least 13 different types of cancer.
By helping patients lose substantial weight, GLP-1 medications may indirectly reduce some of the biological drivers associated with cancer development and progression. This includes lower inflammation, improved hormone balance, and reduced metabolic stress.
4. Possible Direct Effects on Tumor Cells
Researchers have discovered GLP-1 receptors in some tumor tissues, raising the possibility that these medications may have direct effects on cancer biology. However, this area remains under investigation and more research is needed before firm conclusions can be drawn.
Important: What This Study Does NOT Prove
As exciting as these findings are, it’s important to understand the limitations.
This was an observational study, not a randomized controlled trial. That means researchers observed associations but cannot prove that GLP-1 medications directly caused the reduction in cancer progression. Other factors—such as weight loss, healthier lifestyles, or differences between patient groups—may have contributed to the results.
Experts agree that randomized clinical trials are needed before GLP-1 medications can be considered part of standard cancer treatment.
What Does This Mean for Patients?
For individuals already using GLP-1 medications for obesity or type 2 diabetes, the findings are encouraging.
The primary reasons to use GLP-1 medications remain:
- Weight loss
- Improved blood sugar control
- Reduced cardiovascular risk
- Better metabolic health
However, emerging research suggests that these medications may offer additional health benefits beyond weight management, including potential protection against certain obesity-related cancers.
Patients should not start a GLP-1 medication solely to prevent or treat cancer based on current evidence. But for those who qualify for treatment due to obesity or metabolic disease, these findings add to a growing list of potential long-term health benefits.
The Bottom Line: GLP-1 medications and cancer
GLP-1 medications continue to surprise researchers.
A large new study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting found that patients taking GLP-1 medications were significantly less likely to experience progression of certain cancers, including lung, breast, colorectal, and liver cancers.
While more research is needed, these findings strengthen the growing body of evidence that improving metabolic health may have far-reaching benefits beyond weight loss alone.
As scientists continue to explore the relationship between obesity, metabolism, and cancer, GLP-1 medications may prove to be one of the most impactful medical advances of our time.
References
- American Society of Clinical Oncology (ASCO). GLP-1s may help prevent the spread of lung, breast, colorectal, and liver cancers.
- Orland MD et al. “Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.” Journal of Clinical Oncology, 2026.
- Cleveland Clinic Cancer Institute Research Presentation, ASCO Annual Meeting 2026.
